Novartis quietly buries another failed eczema drug, with a $485M hit embedded in the footnotes
Back in late 2016, when Vas Narasimhan was the chief medical officer at giant Novartis, he arranged a buyout of Ziarco primarily so he could get his hands on ZPL389, an oral H4 receptor antagonist that had attracted him with some decent mid-stage data on atopic dermatitis. And he gave it a full-throated shoutout in the release, talking up about how excited he was to make a move on the eczema front.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
